Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
4.9
Journals
IJMS
Special Issues
Current Advances in Gut Microbiota in Human Diseases and Health
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Current Advances in Gut Microbiota in Human Diseases and Health

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Microbiology".

Deadline for manuscript submissions: 20 July 2025 | Viewed by 2316

Special Issue Editor

Dr. Avinash Karpe

E-Mail Website
Guest Editor
Agriculture and Food, Commonwealth Scientific and Industrial Research Organisation (CSIRO), Black Mountain Science and Innovation Park, Canberra, ACT 2601, Australia
Interests: metabolomics; proteomics; analytical biochemistry; future proteins; food and nutrition; fermentation; biomass waste recycling
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Multidrug resistance (MDR), also known as antimicrobial resistance (AMR), is becoming a critical global security issue due to widespread antibiotic misuse and limited development of new drugs. Recent studies highlight a concerning rise in deaths linked to bacterial AMR, emphasizing the urgency of the situation.

While novel drugs are crucial in combating MDR, the role of nutrition in bolstering resilience against pathogens, especially through a healthy gut microbiome, is often overlooked in clinical settings. Understanding how nutrition impacts the gut microbiome's response to AMR is vital for combatting infections effectively.

Exploring the age-old concept of "Food is Medicine" through modern scientific tools can offer insights into the health implications of nutrition practices. Addressing the gaps in knowledge about how different nutritional factors influence the gut microbiome's response to AMR pathogens is essential, especially in the food and nutrition industry.

We invite research focusing on molecular mechanisms addressing AMR/MDR infections and the role of nutrition in fostering a resilient gut microbiome. Contributions bridging microbiological and biochemical insights in human health, agriculture, and nutrition sectors, including veterinary perspectives, are encouraged.

Dr. Avinash Karpe
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial and multidrug resistance (AMR, MDR)
  • gut microbiome
  • systems biology
  • novel technologies
  • principles and mechanism of action
  • food and nutrition
  • food as Medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 1427 KiB  
Article
Exploring the Potential of Oral Butyrate Supplementation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Subgroup Insights from an Interventional Study
by Miloš Mitrović, Verica Stanković Popović, Sanja Erceg, Milena Perišić Mitrović, Ana Dobrosavljević, Andrej Stupar, Petra Vuković, Dušan Zlatković and Petar Svorcan
Int. J. Mol. Sci. 2025, 26(12), 5561; https://doi.org/10.3390/ijms26125561 - 10 Jun 2025
Viewed by 326
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common cause of chronic liver disease and is closely associated with metabolic abnormalities and cardiovascular risks. Butyrate, a short-chain fatty acid produced by gut microbiota, has the potential to enhance liver health by modulating inflammation [...] Read more.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common cause of chronic liver disease and is closely associated with metabolic abnormalities and cardiovascular risks. Butyrate, a short-chain fatty acid produced by gut microbiota, has the potential to enhance liver health by modulating inflammation and supporting gut barrier integrity. This study aimed to investigate and compare the effects of sodium butyrate and calcium butyrate in patients with MASLD. In this single-center, randomized clinical trial, 181 patients with MASLD were enrolled and assigned to receive either sodium butyrate (n = 121) or calcium butyrate (n = 60) supplementation at a daily dose of 1000 mg. The primary endpoint was the change in liver steatosis, measured using the Controlled Attenuation Parameter (CAP) via FibroScan®. Secondary endpoints included liver stiffness, biochemical parameters, hepatic steatosis and fatty liver indices, fecal calprotectin levels, stool short-chain fatty acid levels, and microbiome composition. A subgroup analysis compared responders (a ≥ 5% reduction in CAP) to non-responders. There were no significant changes in CAP values for either group (ΔCAP: sodium butyrate, 0.84; calcium butyrate, −0.23; p = 0.70). Sodium butyrate significantly reduced serum trimethylamine N-oxide and fatty liver index, while calcium butyrate led to a decrease in fecal calprotectin levels. Responders demonstrated a lower body mass index, higher levels of high-sensitivity C-reactive protein and HbA1c, and distinct microbiome profiles, characterized by lower abundance of Subdoligranulum and higher abundance of Catenibacterium. Although butyrate supplementation did not significantly improve liver steatosis as measured by CAP, the differing effects on metabolic and inflammatory markers suggest that there may be potential benefits for specific subgroups of patients with MASLD. Full article
(This article belongs to the Special Issue Current Advances in Gut Microbiota in Human Diseases and Health)
►▼ Show Figures

Figure 1

19 pages, 4650 KiB  
Article
Exploring the Interplay of Gut Microbiota and Systemic Inflammation in Pediatric Obstructive Sleep Apnea Syndrome and Its Impact on Blood Pressure Status: A Cross-Sectional Study
by Chung-Guei Huang, Wan-Ni Lin, Li-Jen Hsin, Tuan-Jen Fang, Hsueh-Yu Li, Chin-Chia Lee and Li-Ang Lee
Int. J. Mol. Sci. 2024, 25(24), 13344; https://doi.org/10.3390/ijms252413344 - 12 Dec 2024
Cited by 1 | Viewed by 1291
Abstract
Obstructive sleep apnea syndrome (OSAS) is prevalent among children and is associated with elevated blood pressure (BP), posing a risk for future hypertension and cardiovascular diseases. While the roles of gut microbiota and systemic inflammation in OSAS pathogenesis are recognized in adults and [...] Read more.
Obstructive sleep apnea syndrome (OSAS) is prevalent among children and is associated with elevated blood pressure (BP), posing a risk for future hypertension and cardiovascular diseases. While the roles of gut microbiota and systemic inflammation in OSAS pathogenesis are recognized in adults and animal models, their impact on pediatric BP remains less understood. This cross-sectional study explored the relationships between polysomnographic parameters, gut microbiota, systemic inflammation, and BP in 60 children with OSAS. Significant associations between specific microbial profiles—including beta diversity and 31 marker microbes—and BP variations were observed. These microbial profiles correlated with significant alterations in systemic inflammation markers like interleukin-17 and tumor necrosis factor-α. Notably, the relative abundance of Acinetobacter was related to fluctuations in these inflammatory markers and BP levels. The research further highlighted the unique microbial and cytokine profiles exhibited by children with different BP levels, indicating a substantial role of gut microbiota and systemic inflammation in influencing pediatric cardiovascular health. The findings suggest integrating gut microbiota management into comprehensive cardiovascular risk strategies for children with OSAS. This initiative underscores the need for further investigations to decode the mechanisms behind these associations, which could lead to innovative treatments for pediatric OSAS. Full article
(This article belongs to the Special Issue Current Advances in Gut Microbiota in Human Diseases and Health)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop